Drug profile · INN
nintedanib
OFEV
nintedanib (OFEV) is a vascular endothelial growth factor receptor inhibitor. Associated with Boehringer Ingelheim Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — nintedanib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 0
- Programs
- 4
- Data quality
- 0.89
Quick answer
nintedanib (OFEV) is a vascular endothelial growth factor receptor inhibitor. Associated with Boehringer Ingelheim Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Vascular endothelial growth factor receptor inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is nintedanib?
nintedanib (OFEV) is a vascular endothelial growth factor receptor inhibitor. Associated with Boehringer Ingelheim Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for nintedanib?
OFEV is a marketed brand name for nintedanib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of nintedanib?
nintedanib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.